MAGNESIUM METALLICUM
Cognitive Dysfunction
Johns Hopkins UniversitySmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 89/ 100
Competitive context
12 Active assets in the Cognitive Dysfunction cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Dalzanemdor Supernus Pharmaceuticals, Inc. | Phase 2 | BB |
BRADANICLINE Targacept Inc. | Phase 2 | B |
Mebufotenin Johns Hopkins University | Phase 2 | B |
cc-5013 St. Joseph's Hospital and Medical Center, Phoenix | Phase 2 | B |
Risperdal Hasanuddin University | Phase 2 | B |
View all 18 →
Same molecule, other indications
MAGNESIUM METALLICUM is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →